Cargando…
An international, randomized, placebo‐controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY‐DLB)
INTRODUCTION: A phase 2b clinical trial, HEADWAY‐DLB, was performed to assess treatment with intepirdine, a serotonin receptor antagonist, in patients with dementia with Lewy bodies (DLB). METHODS: HEADWAY‐DLB was a multinational, double‐blind, randomized, placebo‐controlled study. Two hundred sixty...
Autores principales: | Lang, Frederick M., Kwon, Daniel Y., Aarsland, Dag, Boeve, Brad, Tousi, Babak, Harnett, Mark, Mo, Yi, Noel Sabbagh, Marwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215076/ https://www.ncbi.nlm.nih.gov/pubmed/34189249 http://dx.doi.org/10.1002/trc2.12171 |
Ejemplares similares
-
Developing a core outcome set (COS) for Dementia with Lewy bodies (DLB)
por: Grycuk, Emilia, et al.
Publicado: (2023) -
Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)
por: Lang, Frederick M., et al.
Publicado: (2021) -
Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem)
por: Russo, Mirella, et al.
Publicado: (2022) -
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
por: McKeith, Ian G., et al.
Publicado: (2017) -
REM Sleep Behavior Disorder (RBD) in Dementia with Lewy Bodies (DLB)
por: Chan, Po-Chi, et al.
Publicado: (2018)